A61P 3/06

Sub-Class

Watch

Stats

Description

Class  A61P : THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS


Subclass 3/06: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P 7/00) Antihyperlipidemics

Recent Patents

Patent #TitleFiling DateIssue DatePatent Owner
12257217 Compositions and methods for treating hyperphagia in prader-willi syndromeOct 15, 22Mar 25, 25Purdue Research Foundation
RE50320 APOE mimetic peptides and higher potency to clear plasma cholesterolMay 19, 22Mar 04, 25The UAB Research Foundation; Anji Pharmaceuticals Inc.;
12239620 Methods to decrease triglyceride synthesis in the liverMay 26, 22Mar 04, 25Medicinova, Inc.
12239663 Pharmaceutical composition for prevention or treatment of lysosomal storage disordersJan 23, 20Mar 04, 25BIOGRAPHENE INC.; Seoul National University R&DB Foundation;
12239674 LRH05 isolate, and composition including the same and use thereofJun 17, 21Mar 04, 25SYNBIO TECH INC.
12239683 Synergistic hepatoprotective compositionApr 18, 19Mar 04, 25FFF BIOWORKS LLP
12233044 Cannabidiol and chitosan compositions and methods of using the sameNov 08, 22Feb 25, 25MOR RESEARCH APPLICATIONS LTD
12233098 water-insoluble dietary fiberSep 11, 20Feb 25, 25University of Shanghai for Science and Technology
12226423 Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharideJun 28, 22Feb 18, 25Virginia Commonwealth University; Durect Corporation; The United States Government as Represented by the Department of Veterans Affairs;
12226442 oil and surface-active agentsNov 07, 19Feb 18, 25N.S. OILS LTD.
12221426 Inhibitory material against human body-derived nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like, and anticancer agent comprising same as effective ingredient or pharmaceutical composition comprising same as effective ingredient for treatment of hyperlipidemiaAug 29, 19Feb 11, 25Seoul National University R&DBFoundation; Korea Research Institute of Chemical Technology; National Cancer Center;
12209145 PCSK9 antagonist compoundsJun 30, 22Jan 28, 25Merck Sharp & Dohme LLC
12202809 Benzothia(di)azepine compounds and their use as bile acid modulatorsJun 02, 23Jan 21, 25Albireo AB
12187724 Pyrazolopyridine derivative having GLP-1 receptor agonist effectAug 11, 23Jan 07, 25Chugai Seiyaku Kabushiki Kaisha
12178842 PCSK9 antagonist compoundsOct 31, 22Dec 31, 24Merck Sharp & Dohme LLC
12171738 Compositions and methods for lowering triglyceridesAug 10, 22Dec 24, 24AMARIN PHARMACEUTICALS IRELAND LIMITED
12150975 Therapeutic combinations to treat red blood cell disordersJul 26, 17Nov 26, 24HARTIS-PHARMA SA
12138285 Cholesterol reducing compositions and methods of use thereofMar 06, 23Nov 12, 24Not available
12139497 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disordersMar 21, 23Nov 12, 24Achillion Pharmaceuticals, Inc.
12134636 Immunoglobulins and uses thereofOct 30, 20Nov 05, 24Janssen Pharmaceutica NV

more results

Recent Publications

Publication #TitleFiling DatePub DatePatent Owner
2025/0114,415 METHOD FOR LOWERING CHOLESTEROL AND LIPID LEVELS USING THE ANTRODIA CINNAMOMEA WATER-INSOLUBLE DIETARY FIBERDec 20, 24Apr 10, 25Not available
2025/0092,041 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECTNov 22, 24Mar 20, 25Chugai Seiyaku Kabushiki Kaisha
2025/0082,706 FERMENTED GINSENG RADIX ET RHIZOMA EXTRACT, PRODUCT FOR ALLEVIATING NON-ALCOHOLIC FATTY LIVER DISEASE, METHOD FOR PROMOTING INCREASE OF CONTENT OF AGLYCONE FLAVONOIDS AND/OR SHORT-CHAIN FATTY ACIDS IN GINSENG RADIX ET RHIZOMA EXTRACT, AND METHOD FOR PROMOTING EFFICACY OF GINSENG RADIX ET RHIZOMA EXTRACT IN ALLEVIATING NON-ALCOHOLIC FATTY LIVER DISEASEJun 18, 24Mar 13, 25INFINITUS (CHINA) COMPANY LTD.
2025/0073,185 Composition Including Benzylaminoethanol Derivative as Active Ingredient for Prevention or Treatment of Metabolic DiseaseJul 28, 22Mar 06, 25Not available
2025/0064,926 HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTSJul 31, 24Feb 27, 25Not available
2025/0066,509 ANTI-BETAKLOTHO ANTIBODY AND USE THEREOFDec 29, 22Feb 27, 25Not available
2025/0059,300 METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) WITH AN ANTI-PCSK9 ANTIBODYJul 29, 24Feb 20, 25Not available
2025/0059,540 DOUBLE STRANDED RNA TARGETING ANGIOPOIETIN-LIKE 3 (ANGPTL-3) AND METHODS OF USE THEREOFJun 28, 24Feb 20, 25Not available
2025/0051,765 APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFApr 29, 24Feb 13, 25Not available
2025/0051,457 ASGR INHIBITORSJul 11, 24Feb 13, 25Not available
2025/0041,264 METHOD FOR TREATING DIABETES BY USING ANTRODIA CAMPHORATA COMPOUNDJan 24, 24Feb 06, 25Not available
2025/0032,446 METHODS AND COMPOSITIONS FOR THE BIOSYNTHESIS AND USE OF DEMETHYLATED POLYMETHOXY FLAVONESDec 12, 22Jan 30, 25Board of Trustees Rutgers The State University of New Jersey
2025/0025,421 PREPARATION IN SOLID FORM COMPRISING ACTIVATED CARBON AND CHITOSAN, METHOD FOR PREPARING SAID PREPARATION, COMPOSITION COMPRISING SAID PREPARATION AND USES OF SAID COMPOSITIONJun 10, 22Jan 23, 25Not available
2025/0025,538 METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTSAug 08, 24Jan 23, 25Not available
2025/0026,803 IMMUNOGLOBULINS AND USES THEREOFOct 02, 24Jan 23, 25Not available
2025/0027,089 DOUBLE STRANDED RNA TARGETING PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) AND METHODS OF USE THEREOFJun 21, 24Jan 23, 25Not available
2025/0017,998 SP-8356, EMODIN, AND IT603 ENHANCE BEIGE ADIPOCYTE ACTIVITY AND ALLEVIATE OBESITY AND DIABETES VIA UNCOUPLING PROTEIN 1 (UCP1)-INDEPENDENT MECHANISMJul 03, 24Jan 16, 25Not available
2025/0019,353 BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORSJul 02, 24Jan 16, 25Not available
2025/0009,840 CHOLESTEROL-FREE HIGH-DENSITY LIPOPROTEIN PARTICLESOct 04, 22Jan 09, 25PhoenixBio Co., Ltd.
2025/0009,842 Methods for Regulating Muscle Performance using Fat Specific Protein 27 (FSP27) CompositionsAug 13, 24Jan 09, 25Ohio University

more results

Top Owners in This Subclass

Upgrade to the Professional Level to view Top Owners for this Subclass.Learn More

Patents Issued To Date - By Filing Year

Average Time to Issuance